Cerus Q2 adjusted EBITDA misses estimates, raises 2026 outlook

Cerus

30/07/2026 21:11

Overview
U.S. blood safety tech firm's Q2 product revenue rose 10% yr/yr, total revenue up 5%
Q2 adjusted EBITDA positive but missed analyst expectations
Company raised 2026 product revenue and IFC sales guidance on strong demand

Outlook
Cerus raises 2026 product revenue guidance to $229-$231 mln, up 11%-12% Y/Y
Company increases 2026 IFC sales outlook to $23-$25 mln, up 40%-50% Y/Y
Cerus anticipates regulatory decision on INT200 device in early 2027

Result Drivers
IFC DEMAND - Q2 demand for INTERCEPT Fibrinogen Complex rose about 20% yr/yr, with U.S. IFC sales up, cited by CEO as a key growth driver
BROAD-BASED PRODUCT GROWTH - Product revenue growth driven by increases across all product categories and regions
GROSS MARGIN PRESSURE - Gross margin declined due to weaker U.S. dollar versus euro and higher product costs from inflation

Company press release: ID:nBw3jYbF9a

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Adjusted EBITDA
Miss
$3 mln
$4.17 mln (3 Analysts)
Q2 Gross Margin
 
51.40%
 
Q2 Gross Profit
 
$29.50 mln
 
Q2 Operating Expenses
 
$37.30 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Cerus Corp is $4.50, about 56.8% above its July 29 closing price of $2.87

Reuters Recommended Reads
July 29 - US FDA approves first freeze-dried plasma product 
July 29 - GE Healthcare Q2 revenue rises 5.7% on Pharmaceutical Diagnostics unit strength
July 29 - Boston Scientific Q2 results beat estimates on cardiovascular strength 

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)